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A molecular method for the detection of Pseudomonas pseudomallei was developed on the basis of the
differences in the 23S rRNA sequences of related species of the genus Pseudomonas. An 18-base oligonucleotide
probe, designed following partial sequencing of 23S ribosomal DNA (rDNA), was used for the identification
and detection of P. pseudomallei either by hybridization or by direct PCR. Optimal detection was obtained by
hybridization of the probe with PCR-amplified rDNA rather than with total genomic DNA or colony blots. One
nanogram of template DNA amplified in a PCR mixture containing 14% glycerol could be detected in slot blots
hybridized with the digoxigenin-labelled probe and the lumigen PPD detection system. Amplified rDNA
sequences from 41 P. pseudomallei strains of various origins hybridized with the probe. The probe also
hybridized with three Pseudomonas mallei reference strains under conditions of high stringency but failed to
hybridize with amplified rDNA sequences from other closely related Pseudomonas spp. PCR with a conserved
primer and the 18-base oligonucleotide probe (direct PCR) specifically amplified P. pseudomallei and P. mallei.
By using these methods, approximately 104 P. pseudomallei cells per ml could be detected in artificially
inoculated blood samples and in blood dried on filter paper following Chelex extraction. The detection limit in
blood was increased to 102 cells per ml by concentration of bacteria from 0.5 ml of blood or by a 24-h blood
culture enrichment prior to PCR. Approximately 103 cells per ml were detected in seeded sputum samples. The
detection times by direct PCR and indirect PCR and then probe hybridization were approximately 5 h and 24
h, respectively. These results indicate that amplification of conserved rDNA sequences by PCR directly or by
hybridization with a probe to PCR fragments offers promise for the detection of P. pseudomallei and P. mallei.
Melioidosis, an infectious disease of humans and animals
caused by Pseudomonas pseudomallei, is an important public
health problem of increasing prevalence in southeastern Asia
and northern Australia (1, 8). The causative agent of melioi-
dosis, P. pseudomallei, is a soil saprophyte which is thought to
occupy an ecological niche similar to that of Pseudomonas
cepacia (4), although its distribution has traditionally been
considered to be more restricted, between 20°S and 20°N (11).
A problem in ascertaining the presence of P. pseudomallei in
environmental specimens is isolating and differentiating the
bacterium from the heterogeneous population of organisms
that may be present (22). Clinical investigations are similarly
hampered because P. pseudomallei may be misidentified be-
cause of overgrowth by the normal flora that is commonly
present in specimens (32). Many epidemiological questions
regarding melioidosis are still unanswered, in part because of
the lack of a sensitive system for detecting this organism.
Yabuuchi et al. (39) have recently proposed that the species
belonging to RNA homology group II of the genus Pseudomo-
nas be transferred to a new genus, Burkholderia. Burkholderia
pseudomallei and Burkholderia mallei were found to be genet-
ically indistinguishable, but because of epidemiological dissim-
ilarities, they have remained separate species (39). P. mallei
causes glanders, an exotic disease primarily of horses and
mules that is not found in Australia, and reports of the disease
in other countries are rare (1). There have been no published
reports in which, diagnostically, melioidosis and glanders have
been confused.
Molecular method-based technology is continually being
applied to the detection of many microorganisms in clinical
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specimens (17, 27, 31) and environmental sources (6) because
of the potential utilities of rapid methods with improved
sensitivities and specificities. The 16S and 23S ribosomal genes
are suitable for use in the identification and detection of
taxonomic groups because of the highly conserved nature of
these genes (19). In addition, the detection of rRNA can
increase the sensitivity 1,000-fold or more because of the
multiple copies of the target sequences present in a bacterium
(20). Oligonucleotide probes designed from rRNA sequences
have enabled the specific detection of closely conserved bacte-
rial species in environmental and clinical specimens (6, 26).
PCR has been used to increase the sensitivities of such probes
by amplifying segments of ribosomal DNA (rDNA) before
hybridization (24). PCR of clinical samples has been enhanced
by the development of simplified sample preparation proce-
dures, which minimize the activities of inhibitory substances (7).
The aim of the study described here was to sufficiently
sequence the 23S rRNA of P. pseudomallei to construct an
oligonucleotide probe that is able to specifically distinguish this
species and to apply the developed techniques to the detection
of the organism in artificially inoculated blood and sputum
samples.
MATERUILS AND METHODS
Bacterial strains and DNA extraction. The P. pseudomallei
strains and the Pseudomonas reference strains used in the
study are summarized in Tables 1 and 2, respectively. Strains
were identified phenotypically according to the criteria de-
scribed by Ashdown (2). The tests included growth on the
medium described by Ashdown (2), alkaline phosphatase
production, gentamicin and colistin resistance, and glucose and
maltose oxidation and fermentation. P. pseudomallei, P. cepa-
cia, Pseudomonas aeruginosa, Pseudomonas stutzeri, Pseudomo-
nas gladioli, Pseudomonas marginalis, and Pseudomonas pick-
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TABLE 1. P. pseudomallei strains used in the study
Strain no(s).
Donor laboratory Origin Sourceareference no.
297 NCTC 10276 Human, England CPHL
298 NCTC 1688 Rat, Malaysia CPHL
299 NCTC 10274 Human, Malaysia CPHL
301 NCTC 8016 Sheep ARI
307, 311, 30.307, 30.311, 30.329, Human, Australia PH
329, 332, 30.332, 30.334
334
359, 361 30.359, 30.361 Human, Thailand PH
371 L7016/1 Pig, Australia ARI
377 W2815 Cow, Australia ARI
375, 379 No. 5, No. 10 Water, Australia ARI
380 Searle Human, Australia ARI
385 NCTC 7383 Human, Burma ARI
386 NCTC 6700 Human, England ARI
390 198 Sheep, Australia ARI
396, 405, UQV1844, UQV1853, Human, Australia VSUQ
406 UQV1854
407, 409, UQV1855, UQV1857, Soil, Australia VSUQ
419 UQVI85
421, 423, B6136, B5528/89, Human, Malaysia HUSM
425 P855/91
428 NF 290/31 Human, Thailand NIH
429 NCTC 4845 Monkey, Singapore NIH
432 NR342.30 Human, Thailand NIH
440 9046365 Goat, Australia DPIO
442, 438, 9140682, 9046110, Pig, Australia DPIO
446 9141325
443 9040361 Camel, Australia DPIO
467, 468, 88R, 82, 92, 107 Human, Australia RDH
474, 478
482 76 Water, Australia RDH
aAbbreviated names of donating institutions: CPHL, Central Public Health
Laboratory, Colindale, United Kingdom; NIH, National Institute of Health,
Bangkok, Thailand; PH, School of Public Health and Tropical Medicine, New
South Wales, Australia; ARI, Animal Research Institute, Department of Pri-
mary Industries, Queensland, Australia; VSUQ, University of Queensland
Veterinary School, Queensland, Australia; HUSM, Universiti Sains Malaysia,
Kelantan, Malaysia; RDH, Royal Darwin Hospital, Darwin, Northern Territory,
Australia; DPIO, Oonoomba Veterinary Laboratory, Department of Primary
Industries, Queensland, Australia.
ettii were cultured on brain heart infusion agar (GIBCO) at
37°C. The remaining Pseudomonas species were cultured on
sucrose peptone agar (15) at 28°C. Quarantine regulations in
Australia do not allow the importation of P. mallei cultures;
therefore, a permit was obtained for the accession of purified
P. mallei DNA. DNAs from the three strains of P. mallei were
prepared by one of us (P.M.D.) in the laboratory of T. Y. Pitt,
Central Public Health Laboratory, Laboratory of Hospital
Infection, London, United Kingdom, and were transported to
Australia. The DNA extraction protocols were described pre-
viously (23).
PCR amplification using conserved sequences. Primers
PPMA and PPMC (Fig. 1) were initially selected from homol-
ogous 23S rRNA sequences of P. cepacia (16) and P. aerugi-
nosa (35) to amplify a 1,550-bp fragment. All oligonucleotides
described in Fig. 1 were synthesized on an Applied Biosystems
392 DNA synthesizer by using standard cyanoethyl phosphor-
amidite chemistry, desalted on Sephadex G-25, and lyophilized;
the oligonucleotides were supplied by Bresatech Ltd., Australia.
For PCR amplification, the template DNA was denatured in
PCR buffer with glycerol at 94°C for 10 min by using a DNA
thermal cycler (480; Perkin-Elmer, Norwalk, Conn.); this was
followed by the addition of PCR reagents through the mineral
oil overlay (hot start). The PCR reagent mixture consisted of
TABLE 2. Pseudomonas spp. used in the study
Species and strains Sourcea
P. aeruginosa UQM495 (NCTC 10332) ............................. CC
P. caryophylii 2313Q ............................. ACH
P. cepacia UQM1771 (NCT'C 10743) ............................. CC
P. cepacia THP479 (77) ............................. RDH
P. gladioli UQM1770 (ATCC 10248) ............................. CC
P. mallei NCTC 10229 ............................. CPHL
P. mallei NCTC 10247 ............................. CPHL
P. mallei NCTC 10230 ............................. CPHL
P. pickettii 224499............................. ACH
P. solanacearum UQM1644 ............................. CC
P. marginalis UQM1217 (ATCC 10844) ............................. CC
P. paucimobilis UQM2901 ....... ...................... CC
P. putida UQM739 ............................. CC
P. stutzeri UQM781 (ATCC 17587) ............................. CC
aCC, Culture Collection, Department of Microbiology, University of Queens-
land, Queensland, Australia; CPHL, T. Y. Pitt, Central Public Health Labora-
tory, Colindale, United Kingdom; ACH, A. C. Hayward, Department of Micro-
biology, University of Queensland, Queensland, Australia; RDH, Royal Darwin
Hospital, Darwin, Northern Territory, Australia.
100 pmol of each primer, 200 ,uM deoxynucleotide triphos-
phates, 1.5 U of Taq DNA polymerase (Boehringer Mannheim
GmbH), 14% glycerol, and PCR buffer containing 50 mM KCl,
2 mM MgCl2, and 10 mM Tris (pH 8.8). Amplification (indirect
PCR, i.e., PCR with conserved primer sequences) in the ther-
mocycler included 30 cycles of 1 min at 94°C, 30 s at 65°C, and
2 min at 72°C and a final cycle with an extension step of 10 min
at 72°C. Amplified products were analyzed by electrophoresis in
1% agarose gels in TAE (40mM Tris-acetate, 2 mM EDTA [pH
7.8]) buffer at 60 V for 20 min and were visualized by ethidium
bromide staining.
Sequencing. The 23S rDNA PCR products from P. pseu-
domallei were prepared with the conserved primers PPMA and
PPMC under the conditions described above. Unincorporated
PCR primers and deoxynucleotide triphosphates were removed
by using a Prep-a-Gene DNA binding matrix (Bio-Rad Labora-
tories, Richmond, Calif.). The fragments were sequenced by the
dideoxy-chain termination method (30) by using the Sequenase
version 2.0 sequencing kit (U.S. Biochemical Corp., Cleveland,
Ohio) and by following the conditions for the direct sequencing
of PCR products described by Dorsch and Stackebrandt (13).
Primers PPMB2 and PPMC were used for sequencing.
Nucleotide sequence accession number. The partial se-
quence data for P. pseudomallei 23S rDNA have been depos-
ited in GenBank under accession number U02305.
Probe design, application to hybridization, and direct PCR.
The 388-bp sequences from P. pseudomallei NCTC 4845 and
NCTC 6700 were compared with P. cepacia 23S rRNA se-
quences (16) by using the DNASIS software program (Phar-
macia Biochemicals Inc., Milwaukee, Wis.). An 18-base oligo-
nucleotide probe, PPM2 (Fig. 1), was selected from an area
with the greatest sequence variation and was synthesized by
Bresatech Ltd. as described above. For hybridization, the
probe was end labelled with digoxigenin by using the Genius 6
oligonucleotide tailing kit as described by the manufacturer
(Boehringer Mannheim GmbH). Primer PPM2 in combination
with primer PPMB2 or PPMA (direct PCR) was used to
amplify P. pseudomallei directly, producing products of approx-
imately 75 or 1,125 bp, respectively. PCR was performed at an
annealing temperature of 50°C, and the remaining PCR pa-
rameters were as described above. The products resulting from
PCR with PPM2 and PPMB2 were electrophoresed in Visigel
(Stratagene, La Jolla, California), which was prepared in
accordance with the manufacturer's instructions.
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FIG. 1. Diagrammatic representation of the region of the 23S rDNA of P. cepacia and the positions of the primers. The primer sequences are
as follows: PPMA, 5'-GGTAGCCTGCGAAAAGCTACGGGGGAG-3'; PPMB2, 5'-CCTGCGCGGAACATGTAACGGGGCT-3'; PPMC,
5'-CCACCTGCGTCGGTYllGCGGTACGG-3'. The approximate position of the primer selected from the P. pseudomallei 23S rDNA sequence
(PPM2, 5'-CTCTCCTACCATCGAGAC-3') is 1167 on the P. cepacia sequence.
Slot and colony blot preparation and Southern transfer.
Slot blots were prepared with genomic DNA and with PCR
products amplified by using primers PPMA and PPMC. Ten
micrograms of genomic DNA and 1/10th of the 100-,ul PCR
product amplified from the 41 P. pseudomallei isolates (Table
1) and Pseudomonas spp. (Table 2) were vacuum blotted onto
a nylon membrane by using a slot blot manifold (Bio-Rad
Laboratories). Samples were diluted in 200 [lI of 6 x SSC (1 x
SSC is 0.15 M NaCl plus 0.015 M sodium citrate), heat
denatured, and placed on ice prior to blotting. Slot blot
transfer onto a positively charged nylon membrane (Boehr-
inger Mannheim GmbH) was achieved by following the man-
ufacturer's (Bio-Rad Laboratories) instructions. Colony blots
on nylon membranes were prepared by using the Pseudomonas
spp. (Table 2) and the five P. pseudomallei National Collection
of Type Cultures (NCTC) strains by the method of Ausubel et
al. (5). DNA transfer of PCR products from 1% agarose gels
was achieved by using the VacuGene XL vacuum blotting
system (Pharmacia LKB Biotechnology AB, Uppsala, Sweden)
in accordance with the manufacturer's instructions.
Hybridization and detection. Prehybridization and hybrid-
ization with the digoxigenin-labelled probe and detection with
lumigen PPD was performed according to the Genius System
User's Guide supplied by the manufacturer (Boehringer
Mannheim GmbH). Membranes were prehybridized for 2 h
and were hybridized with 10 pmol of the digoxigenin-labelled
oligonucleotide PPM2 per ml overnight at 45°C in a hybrid-
ization incubator (Robbins Scientific, Calif.). Prior to blocking,
the membranes were washed at room temperature twice in 2 x
SSC-0.1% sodium dodecyl sulfate (SDS) for 5 min and twice in
0.5 x SSC-0.1% SDS for 15 min at 45°C.
Preparation of crude bacterial extracts for PCR. One-
milliliter aliquots of an overnight broth of P. pseudomallei
NCTC 4845 were centrifuged (12,000 x g for 5 min), and the
pellets were resuspended in 200 RI of Chelex solution (40%[wt/wt] Chelex-100 [Bio-Rad Laboratories] in 0.1% [wt/vol]
SDS-1% [vol/vol] Nonidet P-40--1% [vol/vol] Tween 20) (12)
and heated at 95°C for 15 min. The suspension was placed on
ice for 5 min and was centrifuged at 12,000 x g for 30 s, and
10 RI of the supernatant was used in subsequent PCRs. PCR
with a variety of combinations of primers showed that PPMB2-
PPMC (indirect PCR) produced a 500-bp product and
PPMB2-PPM2 (direct PCR) could amplify products from
crude extracts. These combinations were applied to subsequent
reactions for amplification of products from crude samples and
biological extracts.
Inoculation and preparation of clinical samples for PCR.
P. pseudomallei NCTC 4845 was grown overnight in the broth
described by Ashdown (2) and was diluted to a turbidity
equivalent to that of a no. 2 McFarland standard. The broth
was further diluted 10-fold to approximately 3 x 101, 3 x 102,
3 x 103, and 3 x 104 cells per ml in heparinized blood and to
6 x 101, 6 x 102, 6 x 103, and 6 x 104 cells per ml in each
of two sputum specimens obtained from the Princess Alexan-
dra Hospital, Brisbane, Queensland, Australia. These dilutions
were plated onto Ashdown medium (2) without antibiotics to
confirm the purity of the culture and to determine viable cell
counts. Uninoculated controls were also included.
Blood samples were processed by four methods. (i) For direct
processing, 40 [LI of each sample was treated with Chelex
solution as described above for the preparation of crude bacte-
rial extracts, and 2 ,u was used in the PCRs. (ii) For filter paper
processing, 20 pl of each inoculated blood sample was spotted
onto Whatman 3MM chromatography paper and was allowed to
air dry. Each sample was excised with sterile scalpel blades,
added to 200 RI of Chelex solution preheated to 95°C, gently
vortexed, and prepared as described above for direct processing.
(iii) For enrichment, fresh human blood (8 ml) was added
directly to BACTEC 26+ blood culture bottles (Becton Dick-
inson Diagnostic Instrument Systems, Sparks, Md.) with 10-fold
dilutions of P. pseudomallei as described above, and the mixture
was incubated at 37°C ovemight. After 24 h, 40 [lI of each blood
culture was treated with Chelex solution as described above for
direct processing, and viable cell counts and purity checks were
performed as described above. (iv) For the concentration step,
500 RI of each diluted blood sample was pelleted for 1 min at
12,000 x g, resuspended in 100 RI of saponin (1 mg/ml, 37°C),
and repelleted, and the resulting pellet suspension (approxi-
mately 40 RI) was treated with Chelex and prepared for PCR as
described above for direct processing.
Approximately 40 RI of inoculated and uninoculated sputum
samples was treated with Chelex solution and was prepared for
PCR as described above. Both the uninoculated and inoculated
sputum samples were plated onto the selective medium de-
scribed by Ashdown (2), sheep blood agar (5% sheep blood plus
blood agar base [BBL, Cockeysville, Md.]), and MacConkey
medium (Oxoid, Basingstoke, United Kingdom).
RESULTS
Sequence data analysis. The sequence data obtained from P.
pseudomallei NCTC 4845 and NCTC 6700 were identical and
showed that the two strains were 97% homologous with P.
cepacia 23S rRNA at positions 1163 to 1552. An oligonucleo-
tide probe, PPM2 (Fig. 1), from an area of least homology with
P. cepacia was chosen as a potentially specific probe and was
evaluated in hybridization experiments.
PCR. Inconsistent amplification of pure DNA samples by
J. CLIN. MICROBIOL.
 o
n
 O
ctober 21, 2015 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
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PCR was observed (data not shown) by using standard PCR
buffer protocols (28). This was overcome by the addition of
14% glycerol to the reaction mixture, which subsequently
produced consistent amplification of P. pseudomallei rDNA.
Primers PPMA and PPMC amplified a 1,550-bp product from
the purified DNAs of the Pseudomonas spp. listed in Tables 1
and 2, and these reactions were used to evaluate probe (PPM2)
specificity and sensitivity. Chelex preparations of crude cells
could not be amplified with primers PPMA-PPM2 and PPMA-
PPMC. Detection from Chelex preparations was achieved by
amplification with conserved primers (PPMB2-PPMC) and
then hybridization with PPM2 or direct amplification with
PPMB2 (conserved)-PPM2 (P. pseudomallei- and P. mallei-
specific) primers without a hybridization step. These combina-
tions of primers were subsequently used for the detection of P.
pseudomallei in seeded blood and sputum samples.
Specificity of oligonucleotide probe PPM2. All P. pseudoma-
llei isolates conformed with the identification criteria of Ash-
down (2), with the exception of morphology on Ashdown
medium (2). Production of a wrinkled morphology and dye
uptake varied considerably, and strain 479 was atypical in all
colony features (strain 479, which was originally supplied as P.
pseudomallei, was later confirmed to be P. cepacia by the donor
laboratory). Even though 1 pLg of DNA from each isolate was
amplified, the concentration of each PCR product appeared to
vary on a visual basis (i.e., note the variation in the intensities
of the hybridization signals in Fig. 2). For this reason, 10 RI was
applied to slot blots, even though less would have been
sufficient to obtain a hybridization signal for most isolates. The
probe hybridized with PCR products (primers PPMA-PPMC)
from 41 P. pseudomallei and 3 P. mallei strains under condi-
tions of high stringency. No hybridization with the 23S rDNA-
amplified products of the other Pseudomonas spp. was ob-
served. Figure 2 shows the slot blot results for 31 P.
pseudomallei strains, including strain 479 at position El, which
did not hybridize with the probe, and other Pseudomonas spp.
Very faint background signals were observed in slots to which
sterile distilled water was applied as the negative control and in
slots containing hybridization reactions with nonhomologous
species. The difference between a positive and a negative
reaction was distinct.
Sensitivity of oligonucleotide probe PPM2 using purified
DNA. The sensitivity of the probe varied, depending on the
nature of the target DNA. Slot blots prepared from genomic
DNA gave poor signal sensitivities with P. pseudomallei isolates(data not shown). Nonspecific hybridization was observed with
other Pseudomonas spp. by using colony blots (data not
shown). Hybridization of slot blots prepared with amplified
rDNA was the most sensitive and specific. Ten microliters of
the product amplified from 1 ng of template DNA by PCR
could be detected (Fig. 3A). The application of a minimum of
1 pul of amplified product from 1 p.g of template DNA to the
slot blot was detectable (Fig. 3B). By the latter method, the
application of >20 p.l of product produced a signal confined to
the periphery of the slot, while the lower volumes (optimally, 2
[l for this particular PCR product) resulted in a clearer signal
covering the total defined area. Therefore, the application of
too much PCR product to a slot blot could result in confusion
of the actual hybridization outcome (10 p.l was accepted as the
general optimal volume that should be used).
Detection of P. pseudomallei DNA in clinical samples. The
concentrations of viable cells of P. pseudomallei recovered
from inoculated blood and sputum specimens are listed in
Table 3. A total of 1.3 x 104viable cells of P. pseudomallei per
ml were clearly detected in whole blood by hybridization of
PPMB2-PPMC PCR products with probe PPM2 (Fig. 4A and
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FIG. 2. Autoradiogram of slot blot preparations of rDNA frag-
ments amplified from 31 P. pseudomnallei isolates and related Pseudo-
monas spp. by using primers PPMA and PPMC, which were hybridized
with the digoxigenin-labelled oligonucleotide probe PPM2 and visual-
ized with lumigen PPD. The isolates are aligned as follows: Al to
A4, P. pseudomallei, 375, 421, 329, and 429, respectively; BI to B4,
P. pseudomallei 409, 432, 406, and 385, respectively; Cl to C4, P.
pseudomallei 419, 361, 311, and 386, respectively; Dl to D4, P. pseu-
domallei 379, 421, 377, and 298, respectively; El, P. cepacia 479; E2 to
E4, P. pseudomallei 423, 405, and 299, respectively; Fl to F4, P.
pseudomallei 407, 428, 334, and 297, respectively; GI to G4. P.
pseudomallei 482, 442, 446, and 301, respectively; HI to H4, P.
pseudomallei 443, 440, 390, and 380, respectively; C5, P. mallei, 10230;
D5, P. mallei 10229; E5, P. mallei 10247. No hybridization signal was
detected with the following related Pseudomonas spp.: P. cepacia 1171
(A5), P. solaniaceanrun (B5), P. caryophylii (F5), P. gladioli (G5), P.
pickettii (H5), P. stutzeri (A6), P. paucimobilis (B6); P. aeniginiosa (C6),
P. marginalis (D6), and P. putida (E6). Slots F6, G6, and H6 are
negative controls containing no DNA.
B, lanes al to aS) or by PCR with PPMB2-PPM2 (data not
shown). A very faint hybridization reaction was observed at 6.7
x 103 cells per ml (Fig. 4B, lane a3). A total of 2.3 x 102 cells
per ml blood were detected following enrichment for 24 h (Fig.
4A and B, lanes a6 to alO), when the blood culture concentra-
tion was 9.6 x 107 cells per ml (Table 3). Detection was
improved 100-fold when 500 [L1 of blood was concentrated
ng A B yl
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FIG. 3. Sensitivity of the detection of P. pseudomnallei rDNA am-
plified by using primers PPMA and PPMC by hybridization of slot blot
preparations with digoxigenin-labelled oligonucleotide probe PPM2
visualized with lumigen PPD. Lane A, 10 ,ul of the PCR product
amplified from various concentrations of P. pseudoniallei template
DNA, as indicated; lane B, application to slot blot, various volumes (1
to 100 ,ul) of PCR product amplified from 1 p.g of P. pseudomnallei
DNA.
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TABLE 3. Concentrations of P. pseudomallei in artificially
inoculated blood and sputum and in 24-h
blood cultures used for PCR
Count (CFU/ml)a
Sample
Dilution 1 Dilution 2 Dilution 3 Dilution 4
Blood 7.7 x 102 6.7 x 103 1.3 x 104 3.2 x 104
Blood culture (24 h) 9.6 x 107 1.28 x 108 1.8 x 108 9.6 x 108
Sputum 1.5 x 103 1.3 x 104 2.6 x 104 6.4 x 104
a Counts are the averages of duplicate counts on the medium of Ashdown (2)
containing no antibiotics.
prior to the Chelex treatment and PCR preparation (Fig. 4A
and B, lanes all to al5). PCR products were detected in 20 ,ul
of blood containing 3.2 x i04 cells per ml dried on filter paper
(Fig. 4A and B, lanes b7 to bll). No PCR products were
M 1 2 3 4 5
587-
267-
z
89f80 -
64 -
FIG. 5. PCR products prepared from sputum sample 1 by using P.
pseudomallei and P. mallei-specific primer PPM2 and conserved primer
PPMB2 electrophoresed in Visigel-TAE buffer. The molecular size
marker (base pairs) was DNA marker V (Boehringer Mannheim);
positive (+) and negative (-) controls contained purified P.
pseudomallei DNA and no DNA, respectively. Lanes 1 to 5, uninocu-
lated sputum and sputum with dilutions 1 to 4 (Table 3), respectively.
A
a
b
B
+ 1
ag
1 2 3 4 5 6 t MA7 8 910 11 t M
2 3 4 5 6 7 8 9 10 - + 11 12 13 14 15
..~~ ~ ~ ~ ~ ~ ~,,,-.
12 3 4 5 6 7 8 9 10 11
FIG. 4. Detection of P. pseudomallei artificially inoculated into
blood and sputum by PCR amplification with conserved primers
PPMB2-PPMC and hybridization with a digoxigenin-labelled PPM2
probe detected with lumigen PPD. (A) Ethidium bromide-stained
PCR products electrophoresed in 1% agarose-TAE gels; (B) Southern
blot hybridizations. DNA marker VI (Boehringer Mannheim) was
used as the molecular size marker (base pairs); positive (+) and
negative ( - ) controls contained purified P. pseudomallei DNA and no
DNA, respectively. PCR samples included uninoculated blood (lanes
al, a6, all, and b7) and blood inoculated with dilutions 1 to 4 (Table
3) and were treated as follows: direct, lanes al to aS; enrichment, lanes
a6 to alO; concentrated 0.5-ml volumes, lanes all to alS; and filter
paper disks, lanes b7 to bll. PCR of sputa included uninoculated
sputum sample 1 (lane bl), and sputum with dilutions 1 to 4 (Table 3)
(lanes b2 to b5); dilution of sputum sample 2 to 1.5 x 103 CFU/ml
(lane b6).
detected in the negative controls. The detection time, starting
from the time of preparation of the sample for PCR until the
time that hybridization results were available, was approxi-
mately 24 h. The time that it took to obtain a result from direct
PCRs was approximately 5 h. The inclusion of the concentra-
tion step added approximately 15 min to the overall sample
preparation procedure.
Approximately 1.5 x 103 cells of P. pseudomallei per ml
were detected in both sputum samples (Fig. 4A and B, lanes bl
to b6) by using primers PPMB2-PPMC and hybridization with
probe PPM2. Products were amplified from both uninoculated
and inoculated sputum samples; however, the probe did not
hybridize with uninoculated sputum samples. Direct PCR with
primers PPM2-PPMB2 produced weak bands from the inocu-
lated samples but not from the uninoculated samples (Fig. 5).
A Klebsiella sp. and P. aeruginosa were isolated from uninocu-
lated sputum samples 1 and 2, respectively.
DISCUSSION
The current methods used to detect P. pseudomallei from
clinical or environmental samples involve isolation and pheno-
typic characterization of the bacterium (3, 4). The bacterium
can be isolated by using routine culture media, although this
has been more easily achieved for isolation of organisms from
clinical specimens obtained from usually sterile body sites.
Isolation of P. pseudomallei from clinical specimens from
nonsterile body sites (e.g., sputum) and environmental samples
is less successful because P. pseudomallei may be overgrown by
competing normal flora (10). The development of enrichment
or solid media such as Ashdown medium (2) has offered a
more selective isolation process; however, P. pseudomallei
remains subject to misidentification because of its variable
colony morphology and its close phenotypic relationship with
other Pseudomonas spp. In Thailand, where melioidosis is
endemic, the misidentification of P. pseudomallei from clinical
specimens as P. cepacia or P. stutzeri is not uncommon because
of the similar biochemical characteristics, colony morpholo-
gies, and antibiotic susceptibility patterns of the organisms (21,
32). P. pseudomallei and P. cepacia are the most frequently
confused organisms, because they can both be resistant to
gentamicin and colistin (9).
PCR and hybridization have the potential to provide an
alternative procedure for detecting and identifying P.
pseudomallei. rRNA sequences are highly specific for most
organisms and are the basis for the definition of phylogenetic
J. CLIN. MICROBIOL.
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relationships and species identification (34). Theoretically, one
could design oligonucleotide probes which are capable of
discriminating rRNAs that differ by a single nucleotide (36)
and PCR can be used to amplify the target sequences. In the
present study, we investigated the feasibility of using these
techniques to detect P. pseudomallei.
We succeeded in developing a probe which specifically
detected P. pseudomallei and P. mallei. Hybridization with P.
mallei rDNA was not surprising because of the similarities
between these species. Antigenically, the two species are
similar (25); and cellular lipids, fatty acid composition, DNA-
DNA homology values, and 16S rRNA sequences have been
used to demonstrate their close genetic similarities (39).
Melioidosis bears a striking resemblance to glanders, both
clinically and in pathology, but it is epidemiologically dissimilar
(29). Melioidosis is endemic in southeastern Asia and the
tropics (11), whereas glanders was widespread throughout
Europe (29). Unlike melioidosis, which is pathogenic for a
wide range of animals, glanders is primarily a disease of horses,
mules, and donkeys, and other animals are rarely or are not
susceptible. Glanders is now rare because of control measures
and the replacement of horse-drawn vehicles with mechanical
conveyances (1), although sporadic cases of glanders still occur
in animals in Asia, Africa, and South America (29). While the
detection of both P. pseudomallei and P. mallei is a limitation
of this procedure, it is not considered a problem in countries
where melioidosis is endemic but glanders is exotic, e.g.,
Australia. When both diseases are present, the differences in
the phenotypic characteristics of the species could be used in
selective isolation techniques prior to PCR.
The difficulty in obtaining amplified products for sequence
analysis in the present study led to the investigation of various
PCR conditions for the optimization of P. pseudomallei DNA
amplification. Glycerol has been found to be a useful cosolvent
to enhance PCR amplification of GC-rich DNA templates and
for the amplification of long fragments (33). The addition of the
solvent to the PCR mixture resolved the amplification difficul-
ties that were likely due to the high GC content ratio of the
DNA of P. pseudomallei. Variation in the intensity of the slot
blot hybridization signals obtained with PCR products from the
P. pseudomallei strains could be explained by strain-to-strain
variation in the number of target DNA copies, either by the
presence of extraneous rRNA or by the presence of various
numbers of rDNA gene copies. Multiple copies of genes coding
for Escherichia coli rRNA have been described previously (37).
The probe and PCR described here can be used for both the
detection and the identification of P. pseudomallei. The clinical
isolates included in the study had colony morphologies and
phenotypic profiles typical of P. pseudomallei, in contrast to the
soil isolates, which had variable colony morphologies but
otherwise conformed with commonly used identification crite-
ria (2). Strain 479 was originally identified by the donor public
health laboratory as P. pseudomallei, but it did not hybridize
with the probe. This strain had the phenotypic traits (2) of P.
pseudomallei but had a colony morphology on Ashdown me-
dium (2) identical to that of the reference P. cepacia strain.
The molecular methods described here have potential to be
developed as identification tools, particularly for studies with
environmental samples.
Practical sample preparation methods are required if the
techniques described here are to be used in clinical laborato-
ries. Boiled cell lysates can be used as suitable templates for
PCR; however, clinical specimens may contain polymerase
inhibitors which cannot be inactivated by treatment at high
temperatures alone (12). Chelex-100 and heat treatment have
been used to prepare extracts suitable for gene amplification
from pure cultures (12) and clinical samples (18). We found
that this was not successful for P. pseudomallei by using primers
that amplify fragments larger than 1,000 bp, but was effective
with primers that amplify products of 500 bp or less.
There is no information available on the concentration of P.
pseudomallei present in clinical specimens. Freeman (14) re-
ported that the concentration of bacterial cells in blood samples
from septicemic patients is often less than 1/ml. Some cases of
septicemic melioidosis are confirmed only after 7 days of blood
culture (38), and Thai researchers recommend that blood
cultures be observed for up to 2 weeks (32), suggesting that the
number of bacteria present may be low. The detection levels
determined in the present study were much less sensitive, and
alternate preparatory methods for concentrating target nucleic
acid, including the direct detection of rRNA (17, 24), are being
evaluated. The methods evaluated could be made more sensi-
tive by concentrating the cells from larger blood volumes prior
to Chelex treatment.
Regardless of the requirement for hybridization, PCR offers
a more rapid diagnostic test. Patients with septicemic melioid-
osis, particularly those with fulminant melioidosis, may die
before blood cultures become positive (8). P. pseudomallei is
resistant to many empirical antibiotics; thus, the timing for
treatment with the correct regimen is critical for patient
management (1). Detection of the organism may be possible
within 5 to 24 h, depending on the number of cells present.
These techniques require clinical evaluation in parallel with
culture and serological diagnostic tests.
The lung is the most common site of involvement in
localized melioidosis (9). In a Thai study of septicemic mel-
ioidosis (8), it was observed that the primary source of
infection of almost a quarter of the cases was pneumonia. Lung
involvement can be primary or secondary to septicemia (9). In
the case of a primary infection of pulmonary melioidosis, a
highly purulent sputum is produced (9). Approximately 103
cells per ml of sputum were detected either by direct PCR or
following PCR and hybridization. The concentration of P.
pseudomallei expected in sputum would vary considerably,
depending on the severity of the disease and the quality of the
specimen. The sputum specimens used in the present study
were contaminated with other species, in particular, a Pseudo-
monas sp., which would account for the PCR products that
were amplified; however, hybridization confirmed the presence
of PCR products homologous to P. pseudomallei.
The application of PCR and hybridization in diagnostic
laboratories may not be feasible in some areas where melioi-
dosis is endemic at present; however, advances in the tech-
niques and the development of user-friendly adaptations of the
techniques are progressing rapidly. The potential to detect the
bacterium in blood dried on filter paper offers a mechanism for
the transport of specimens from areas with limited laboratory
facilities to a central laboratory. Evaluation of this technique
for use with environmental isolates of P. pseudomallei is in
progress. The detection of P. pseudomallei in other clinical
samples, e.g., pus, which is commonly encountered with mel-
ioidosis, also requires attention. The technique offers consid-
erable potential for use in the diagnosis and the detection of P.
pseudomallei and as a tool for further research into the
pathogenesis of melioidosis.
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